KOD Kodiak Pharma: Net earnings per share for the last four quarters

Public company logo of Kodiak Sciences Inc (KOD)

Strict FDA oversight of injection safety creates risks for the patient base, yet the trailing twelve months (TTM) annual EPS growth illustrates the business's real potential. The value of 0.90 represents the latest metric reading, confirming the success of the ABC platform in reducing injection frequency. Its status as a retinal treatment innovator and the trust of ophthalmologists make Kodiak Sciences Inc. (KOD) a key market player.

KOD Kodiak Pharma Earnings per share for the last twelve months (02/11/2024 - 11/18/2026)

kodiak.com - analytical breakdowns and key metrics (KOD)

- price and consensus price forecast:
Fundamental company valuation:KOD - Kodiak Sciences Inc
Finished products of Kodiak Sciences Inc.

This indicator measures the annual growth of net income per share over a rolling twelve-month period, allowing investors to assess capital scaling rates relative to past performance. An analysis of the annual percentage growth of EPS TTM for Kodiak Sciences Inc. (KOD) highlights the macro-resilience of biopharmaceuticals, where demand for retinal therapy remains independent of economic cycles, turning current values into a marker of the company's efficiency in accessing capital.

Competitor analysis

Net earnings per one share for the last twelve months Alcon Inc|BLCO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Glaukos Medical (GKOS)|Earnings per share for the last twelve months apellis.com|Belite Bio (BLTE) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) VRDN (Viridian Corp)|LENZ Corp (LENZ) - Net earnings per one share for the last twelve months|OCS: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months eyepointpharma.com|ALDX: Net earnings per share (EPS TTM)|KALA BIO, Inc. (KALA) - Net earnings per share (EPS TTM)|IRD (Opus Genetics Inc) - Net earnings per share (EPS TTM)|OKYO: Earnings per share for the trailing year|Net earnings per share for the last 12 months ADVM (adverum.com)|OTLK - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CLSD (Clearside Biomedical Inc)|Earnings per share for the trailing year NBY|Kiora Pharmaceuticals, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ALIM (Alimera Sciences, Inc.)|EYEN (Eyenovia Corp) - Net earnings per share for the last 12 months|Guardion Health Science - Earnings per share for the trailing year|Earnings per share for the last twelve months Ocuphire Pharma, Inc.|Opthea Ltd. (OPT) - Net earnings per share for the last four quarters